Edgen Stock·Sep 09 2025, 04:52戻る
戻る
AMI Pharm's AYP-101 Advances to Phase 3, Poised to Impact Nonsurgical Fat Reduction Market
Edgen Stock·Sep 09 2025, 04:52
[1] AMI Pharm's AYP-101 Shows Promise in Phase 2 Trial, Signaling a Breakthrough in Nonsurgical Fat Reduction (https://finance.yahoo.com/news/ami-pharms-ayp ...)[2] AMI Pharm's double chin treatment enters phase 3 clinical trial By Investing.com (https://vertexaisearch.cloud.google.com/groun ...)[3] Injection Lipolysis Market Size, Share | CAGR of 9.5% (https://vertexaisearch.cloud.google.com/groun ...)